Late gadolinium enhancement CMR for detecting myocardial injury after cancer therapy: a real-world observational study - Scorecard - MDSpire

Late gadolinium enhancement CMR for detecting myocardial injury after cancer therapy: a real-world observational study

  • By

  • Xi Liu

  • Yue Gao

  • Zhen Wang

  • Wei-Feng Yan

  • Rui Shi

  • Yuan Li

  • Ying-Shi Sun

  • Zhi-Gang Yang

  • May 1, 2026

  • 0 min

Share

Clinical Scorecard: Utilizing Late Gadolinium Enhancement Cardiac MRI to Identify Myocardial Damage Following Cancer Treatment: An Observational Study in a Real-World Setting

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationOncology patients undergoing various cancer therapies, including chemotherapy, immunotherapy, and radiotherapy.
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement cardioprotective measures based on LGE findings, such as adjusting chemotherapy regimens or adding cardioprotective agents.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Monitor for cardiotoxicity using CMR imaging and biomarkers such as NT-pro BNP and troponin T.

        Clinical Best Practices

        • best_practice_4

        References

        Original Source(s)

        Late gadolinium enhancement CMR for detecting myocardial injury after cancer therapy: a real-world observational study

        • by Xi Liu, Yue Gao, Zhen Wang, Wei-Feng Yan, Rui Shi, Yuan Li, Ying-Shi Sun, Zhi-Gang Yang

        • May 1, 2026

        Related Content

        Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

        Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

        Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review